User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

1968

Interactions with Platform & by Email *

INTERACTIONS

354

Unique # Participated *

PARTICIPANTS

79

Responses Validated *

VALIDATIONS

18

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Sleep Disorders Market – A Prelude.....II-1
Narcolepsy – A Chronic Neurological Sleep Disorder.....II-1
Narcolepsy Therapeutics Market – A Small, Yet Growing Market.....II-1
1$120
   Cephalon’s Provigil – The Market Leader.....II-2
Provigil and Xyrem Continue to Tussle for Dominance.....II-2
Xyrem – The Other Approved Treatment for Narcolepsy.....II-2
Provigil’s Successor, Nuvigil to Retain Cephalon’s Leadership.....II-2
2$175
   Price Increase of Provigil to Aid Patient Shift to Nuvigil.....II-4
Concerns Raise Over Safety of Provigil.....II-4
Cephalon Faces Lawsuit for Suspected Blockage of Provigil’s Generics.....II-4
1$120
   Jazz Pharmaceuticals Settles Lawsuit on Xyrem.....II-51$120
   Sleep Physiology in Narcoleptics.....II-6
Etiology.....II-6
Hereditary.....II-6
1$120
   Variants in HLA Genes.....II-7
Hypocretin Deficiency.....II-7
Symptoms.....II-7
Excessive Daytime Sleepiness (EDS).....II-7
1$120
   Cataplexy.....II-8
Sleep Paralysis.....II-8
Hallucinations.....II-8
Automatic Behavior.....II-8
Frequency and Duration of Sleep Episodes.....II-8
1$120
   Diagnosis.....II-9
Polysomnogram.....II-9
Multiple Sleep Latency Test (MSLT).....II-9
Epworth Sleepiness Scale.....II-9
Spinal Fluid Analysis.....II-9
Psychological and Social Effects.....II-9
2$175
   Drug therapy.....II-11
Treatment for EDS.....II-11
Modafinil (Provigil).....II-11
1$120
   Select Drugs Commonly Used to Treat EDS - Advantages and Disadvantages.....II-12
Treatment for Cataplexy.....II-12
Xyrem: The Only FDA-approved Drug for Cataplexy.....II-12
Lifestyle Changes and Behavioral Treatment.....II-12
1$120
   Alternative Remedies.....II-131$120
   Watson Files ANDA for Generic Nuvigil, Cephalon Sues Watson.....II-14
Cephalon Files Application with US FDA for Nuvigil to Treat Jet Lag.....II-14
Cephalon Files Suit against Mylan Alleging Patent Infringement.....II-14
Cephalon Files Patent Infringement Lawsuit Against Teva for Nuvigil.....II-14
1$120
   Mitsubishi Tanabe Withdraws NDS for Modafinil.....II-15
Barr Laboratories Initiates Voluntary Recall of Generic Amphetamine.....II-15
Cephalon Obtains FDA Clearance to Market Nuvigil for Treating EDS.....II-15
1$120
   Nocturna Sleep Centers Signs Deal with Medical Center of McKinney.....II-16
Cephalon Launches NUVIGIL Tablets.....II-16
Davie County Hospital Adds New Sleep Laboratory.....II-16
Addrenex Inks Licensing Agreement with SK Holdings.....II-16
1$120
   Graymark Healthcare Purchases Avastra Eastern Sleep Centers Inc......II-17
SDC Holdings Signs Agreement with Medical Center of Plano.....II-17
Ligand Acquires Neurogen.....II-17
Cephalon Signs Federal Multi-State Agreement with The State of Utah.....II-17
1$120
   Paladin Labs Buys Dexedrine from GlaxoSmithKline.....II-18
St. Catherine Establishes Sleep Disorders Center.....II-18
SCOA Takes Over Sleep Holdings.....II-18
Graymark Healthcare Acquires SDG and Nocturna Sleep.....II-18
1$120
   Arena Pharmaceuticals, Inc. (US).....II-19
Cephalon, Inc. (US).....II-19
Evotec AG (Germany).....II-19
Hypnion, Inc. (US).....II-19
1$120
   Jazz Pharmaceuticals, Inc. (US).....II-201$120
   Table 1: World Recent Past, Current & Future Market Analysis for Narcolepsy Therapeutics - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-211$300
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com